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1. A synopsis of the normal physiology of neurotransmission in man
There are about 1011 neurons and 1014 synaptic connections in the human brain. 
The neural circuitry is continuously sculpted in response to experience, modified as 
we learn and store memories, and irreversibly altered by the gradual loss of neurons 
and connections as we age [1].
Neuronal signals are transmitted from cell to cell at synapses. When an action 
potential arrives at the presynaptic site, the depolarization of the membrane opens 
voltage-gated calcium channels that are clustered in the presynaptic membrane. 
Calcium influx triggers the release of neurotransmitters which are stored in mem-
brane-enclosed synaptic vesicles and released by exocytosis. The neurotransmitter 
provokes an electrical change in the postsynaptic cell by binding to and opening 
transmitter-gated ion channels. After the neurotransmitter is secreted into the 
synaptic cleft, it is rapidly removed: it is either destroyed by specific enzymes in 
the synaptic cleft or taken up by the presynaptic nerve terminal or by surrounding 
glial cells. Reuptake is mediated by a variety of Na+-dependent neurotransmitter 
symporters. The cycling of neurotransmitters allows cells to keep up with the high 
rates of release [1–3].
The chemical or electrical synapses can be excitatory or inhibitory. Excitatory 
neurotransmitters open cation channels, causing an influx of Na+ and also Ca+ 
in many cases, which reduces the threshold to fire an action potential. Inhibitory 
neurotransmitters open Cl− or K+ channels, thereby making it difficult to depolarize 
the cell membrane. Depending on the secretion milieu, the type of the receptors 
they bind to, and the ionic conditions that they encounter, transmitters may be 
either inhibitory or excitatory. For example, acetylcholine may have inhibitory or 
excitatory effects depending on the type of the receptor it binds to. Usually glu-
tamate and serotonin are excitatory, whereas γ-aminobutyric acid and glycine are 
inhibitory [1–4]. All neurotransmitter receptors fall into one of these classes based 
on their signaling mechanisms:
1. Ionotropic receptors—ion channels present at fast chemical synapses. 
Example: acetylcholine receptor of skeletal muscle cells is a transmitter-gated 
ion channel which is opened transiently by acetylcholine released from the 
nerve terminal at a neuromuscular junction.
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2. Metabotropic receptors—also called G protein-coupled receptors. Signaling 
via is these receptors is somewhat slower, more complex, and longer lasting in 
its effects. For example: hormones such as parathyroid hormone operate via G 
protein-coupled receptors [1].
Biogenic amines such as dopamine, norepinephrine, serotonin, and histamine 
manifest their effects either directly or indirectly via their specified receptors [1].
2. Biogenic amines in human disease
Any dysfunction that occurs in the aforementioned physiological setups in 
the organism may be associated with a disease state, mostly with neurological 
consequences, and therapy is aimed at inducing the recovery of the dysfunctional 
pathway via drugs or, most recently, the gene therapy, which is elaborating ground-
breaking results [5].
Disorders of neurotransmission in the human are either due to the lack of synthesis 
of the neurotransmitter, disordered synapse due to external insults such as trauma, 
autoimmunity, or impaired or enhanced receptor-ligand interaction at the postsynaptic 
area. The list of the neurogenerative diseases, the inborn errors of metabolism associated 
with dysfunctional neurotransmission, is not exhaustive and is discussed elsewhere [6].
From the endocrinologist’s perspective, excess of biogenic amines includes many 
rare endocrine neoplasias such as pheochromocytomas (PHEO) and paraganglio-
mas (PGL). The carcinoid syndrome, a constellation of clinical symptoms of bio-
genic amine excess particularly of serotonin, is much rarer in clinical practice, and 
it is usually observed in the context of clinically manifest neuroendocrine tumors, 
such as midgut carcinoids. In the pediatric patient, these syndromes of amine excess 
are usually associated with hereditary syndromes of endocrine neoplasia, such as 
von Hippel-Lindau disease and multiple endocrine neoplasia (MEN) type 2 syn-
drome, whereas sporadic cases are more common in the adult [7]. The diagnosis of 
amine excess states is challenging since single measurement of the culprit molecules 
via standard laboratory tests is often inconclusive and full of caveats that mandate 
repeat measurements of the suspected amines and/or their metabolites. Below is 
a brief description of catecholamine excess related tumors as an example to how 
biogenic amine excess may relate to human disease.
Pheochromocytomas and paragangliomas (PGL) are uncommon neuroendo-
crine tumors of neural crest origin, with the former being of adrenal medulla origin 
and the latter originating from sympathetic and parasympathetic system. All func-
tional PHEO/PGL produce and metabolize catecholamines and contain chromaffin 
tissue, which refers to the brownish black color due to oxidation of catecholamines 
after staining with chromium salts. Pheochromocytomas comprise the majority of 
the tumors in the pediatric patient [7].
Dopamine, norepinephrine, and epinephrine are biogenic amines collectively 
referred to as catecholamines. These neurotransmitters and hormones are involved in 
regulation of numerous physiological processes and development of neuropsychiatric 
and cardiovascular diseases. They are synthesized from tyrosine, which is converted 
to 3,4-dihydroxyphenylalanine (DOPA) by the enzyme tyrosine hydroxylase, the 
rate-limiting enzyme in catecholamine synthesis. Decarboxylation and hydroxylation 
of dopa yield dopamine and norepinephrine, respectively. Norepinephrine is then 
converted to epinephrine via the enzyme phenylethanolamine N-methyltransferase.
The complex actions of norepinephrine and epinephrine are mediated by the G 
protein-coupled alpha- and beta-adrenergic receptors, whereas dopamine binds to a 
different class of metabotropic receptors.
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The clinical presentation PHEO/PGL is variable. Owing to the neuroendocrine 
origin, they might co-secrete other hormones that result ectopic hormone excess, 
such as gigantism due to growth hormone-releasing hormone, hypercalcemia due 
to parathyroid hormone-related peptide, or secretory diarrhea due to vasoactive 
intestinal peptide. The clinical symptoms and signs of functional PHEO/PGL also 
depend on differences in catecholamine secretion and release as individual patient 
sensitivities to catecholamines. Signs of catecholamine excess include hyperten-
sion, headaches, palpitations, diaphoresis (less common in children), orthostatic 
hypotension, pallor, tremor, and anxiety. Depending on the location of the tumor, 
nonspecific signs and symptoms include blurred vision, abdominal pain, diarrhea, 
or behavioral problems/decline in school performance [7].
The diagnosis of excess catecholamine secretion due to PHEO/PGL has been 
facilitated by the development of assays sensitive to diagnose these entities; mea-
surements of fractionated metanephrine and normetanephrine in plasma and urine 
are considered the primary diagnostic tests in the initial evaluation of suspected 
PHEO/PGL. An elevation of metanephrines greater than fourfold above the refer-
ence range is considered indicative of a catecholamine secreting tumor [8]. It should 
be noted that some PGL can be nonfunctional and may be diagnosed incidentally or 
due to clinical signs and symptoms owing to their anatomical position, as is the case 
in some paragangliomas of the head neck which arise from parasympathetic gan-
glia. Catecholamine-secreting tumors may be noradrenergic as in tumors associated 
with von Hippel-Lindau disease and familial PGL or adrenergic as seen in tumors 
that arise sporadically or in the context of MEN type 2 and neurofibromatosis type 
1. Dopamine-secreting tumors are very rare and typically extra-adrenal succinate 
dehydrogenase-mediated paragangliomas. Measurement of methoxytyramine may 
be of help in this context, but the test is not widely available [9]. Chromogranin A is 
also another effective tumor marker that may correlate with tumor size and malig-
nant potential.
Radiographic studies and in selected cases, molecular genetic testing should be 
planned once the diagnosis of catecholamine secreting tumor is highly considered. 
Further information on management of PHEO/PGL is discussed elsewhere [7].
The expanding knowledge on synthesis and function of biogenic amines may 
pave the path for enhanced medical treatment of disease states of owing to biogenic 
amine excess. Recent studies have also shown that biogenic amines have additional 
important roles as signaling molecules mediating the function of the “microbiota-
brain-gut” axis [10]. The potential role of biogenic amines in this axis is an exciting 
new area of medicine that awaits for further studies.
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